Insulin efsitora alfa

Insulin efsitora alfa is a novel insulin analog developed by Eli Lilly for the treatment of diabetes. Its glycemic control and safety were found similar to insulin degludec in a phase II trial.

Research

A systematic review and metanalysis of insulin efsitora alfa, published in 2024, found that it may be useful in the management of type1 and type2 diabetes.